Vanda Gains Japan Orphan Status for Imsidolimab
WASHINGTON, May 27, 2026 Vanda Pharmaceuticals Inc. has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has...
Vanda Pharmaceuticals
Advertisement
Vanda Launches NEREUS First Motion Sickness Drug
Washington, United States | May 1, 2026 Vanda Pharmaceuticals Inc. has announced the U.S. commercial availability of NEREUS™ (tradipitant),...
Vanda Pharma Publishes Phase III Imsidolimab Data
WASHINGTON, April 28, 2026 Vanda Pharmaceuticals Inc. has announced the publication of pivotal Phase III clinical data evaluating imsidolimab,...
Vanda Urges FDA to Reject Extended Drug Review Timelines
WASHINGTON, April 9, 2026 Vanda Pharmaceuticals Inc. has publicly called on the U.S. Food and Drug Administration (FDA) to...
Vanda Initiates Thetis Trial for GLP-1 Vomiting Prevention
WASHINGTON, April 8, 2026 Vanda Pharmaceuticals Inc. has announced the initiation of the Thetis clinical trial evaluating NEREUS™ (tradipitant)...
Advertisements
FDA Approves BYSANTI for Bipolar I and Schizophrenia
WASHINGTON, Feb. 20, 2026 — Vanda Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) has approved BYSANTI™...
FDA Approves NEREUS™, First New Motion Sickness Drug in 40 Years
Washington, D.C. | December 30, 2025 — Vanda Pharmaceuticals Inc. has announced U.S. Food and Drug Administration (FDA) approval...
FDA Clears Path Forward for Vanda’s Motion-Sickness Drug Development
WASHINGTON, D.C., December 4, 2025 — The U.S. Food and Drug Administration (FDA) has lifted its partial clinical hold...
FDA Advances Tradipitant Review for Motion Sickness Relief
Washington, D.C., November 28, 2025 In a significant regulatory development, Vanda Pharmaceuticals Inc. has announced major progress on tradipitant,...
Advertisement
